Page last updated: 2024-12-10

1-(4-hydroxybenzyl)imidazole-2-thiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(4-hydroxybenzyl)imidazole-2-thiol is a chemical compound with the molecular formula C11H12N2OS.

**Here's what we know about this compound:**

* **Structure:** It's a complex molecule consisting of an imidazole ring (a five-membered ring containing two nitrogen atoms) with a sulfur atom at position 2. A 4-hydroxybenzyl group (a benzene ring with a hydroxyl group and a benzyl group) is attached to the nitrogen atom at position 1.
* **Properties:** It's likely to be a solid at room temperature, and its exact properties are not widely documented.

**Importance in Research:**

The importance of 1-(4-hydroxybenzyl)imidazole-2-thiol in research is not clear from readily available information. It's possible that it's a compound with potential applications in:

* **Pharmaceutical research:** The presence of a sulfur atom and an imidazole ring could make it relevant in the development of drugs targeting specific biological targets.
* **Materials science:** The unique structure might have interesting properties useful in creating new materials.
* **Organic synthesis:** It could serve as a starting material or a reagent in synthetic reactions.

**It's important to note that:**

* Without further context or specific research findings, it's difficult to definitively state the significance of this compound.
* You may need to consult specialized databases or research publications focused on imidazole derivatives, sulfur-containing compounds, or related areas to find more specific information about its potential applications.

If you have a specific research question related to this compound, please provide more details, and I might be able to offer more relevant information.

1-(4-hydroxybenzyl)imidazole-2-thiol: RN & structure given in first source; RN not in Chemline 3/87 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035523
CHEMBL ID164747
SCHEMBL ID1320600
SCHEMBL ID10621224
MeSH IDM0145275

Synonyms (36)

Synonym
EU-0100585
NCGC00015512-01 ,
lopac-h-6892
LOPAC0_000585
1-(4-hydroxybenzyl)imidazole-2-thiol
NCGC00093964-02
NCGC00093964-01
NCGC00015512-02
H 6892
NCGC00015512-04
CHEMBL164747 ,
3-[(4-hydroxyphenyl)methyl]-1h-imidazole-2-thione
4-(2-mercapto-imidazol-1-ylmethyl)-phenol
bdbm50014968
1-(4-hydroxy-benzyl)-1,3-dihydro-imidazole-2-thione
HMS3261F12
SCHEMBL1320600
CCG-204674
NCGC00015512-03
1-hbit
95333-64-5
LP00585
tox21_500585
NCGC00261270-01
SCHEMBL10621224
AKOS026729547
DTXSID20241812
sr-01000075914
SR-01000075914-1
1-(4-hydroxybenzyl)imidazole-2-thione
4-[(2-sulfanyl-1h-imidazol-1-yl)methyl]phenol
Z2286614991
SDCCGSBI-0050567.P002
4-((2-mercapto-1h-imidazol-1-yl)methyl)phenol
EN300-157294
PD015107

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor."( Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
DeWolf, WE; Erickson, RW; Flaim, KE; Frazee, JS; Kaiser, C; Kruse, LI; Ross, ST; Sawyer, JL; Wawro, J; Wise, M, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency1.25890.02827.055915.8489AID895; AID928
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency43.35170.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926
hypothetical protein, conservedTrypanosoma bruceiPotency16.94410.223911.245135.4813AID624147
regulator of G-protein signaling 4Homo sapiens (human)Potency29.93490.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.07790.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.02820.540617.639296.1227AID2364; AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
DNA polymerase betaHomo sapiens (human)Potency35.48130.022421.010289.1251AID485314
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency100.00000.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency0.00080.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dopamine beta-hydroxylaseHomo sapiens (human)IC50 (µMol)2.57041.20232.07793.0000AID62155; AID62281
Dopamine beta-hydroxylase Bos taurus (cattle)IC50 (µMol)2.60000.05001.49432.6000AID61955; AID61961; AID62275
Dopamine beta-hydroxylase Bos taurus (cattle)Ki0.15130.04100.13220.3440AID61993; AID62121; AID62122
Dopamine beta-hydroxylaseRattus norvegicus (Norway rat)IC50 (µMol)2.58520.70001.65452.6000AID62150; AID62278
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)2.57040.00501.35524.6000AID62278
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dopamine beta-hydroxylase Bos taurus (cattle)Kis0.16230.04100.13200.3440AID62126; AID62131; AID62136
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
blood vessel remodelingDopamine beta-hydroxylaseHomo sapiens (human)
response to amphetamineDopamine beta-hydroxylaseHomo sapiens (human)
leukocyte mediated immunityDopamine beta-hydroxylaseHomo sapiens (human)
chemical synaptic transmissionDopamine beta-hydroxylaseHomo sapiens (human)
memoryDopamine beta-hydroxylaseHomo sapiens (human)
locomotory behaviorDopamine beta-hydroxylaseHomo sapiens (human)
visual learningDopamine beta-hydroxylaseHomo sapiens (human)
homoiothermyDopamine beta-hydroxylaseHomo sapiens (human)
vasoconstrictionDopamine beta-hydroxylaseHomo sapiens (human)
dopamine catabolic processDopamine beta-hydroxylaseHomo sapiens (human)
norepinephrine biosynthetic processDopamine beta-hydroxylaseHomo sapiens (human)
glucose homeostasisDopamine beta-hydroxylaseHomo sapiens (human)
fear responseDopamine beta-hydroxylaseHomo sapiens (human)
maternal behaviorDopamine beta-hydroxylaseHomo sapiens (human)
positive regulation of vasoconstrictionDopamine beta-hydroxylaseHomo sapiens (human)
behavioral response to ethanolDopamine beta-hydroxylaseHomo sapiens (human)
response to painDopamine beta-hydroxylaseHomo sapiens (human)
leukocyte migrationDopamine beta-hydroxylaseHomo sapiens (human)
positive regulation of cold-induced thermogenesisDopamine beta-hydroxylaseHomo sapiens (human)
regulation of vascular associated smooth muscle cell proliferationDopamine beta-hydroxylaseHomo sapiens (human)
regulation of vascular endothelial cell proliferationDopamine beta-hydroxylaseHomo sapiens (human)
regulation of extrinsic apoptotic signaling pathwayDopamine beta-hydroxylaseHomo sapiens (human)
octopamine biosynthetic processDopamine beta-hydroxylaseHomo sapiens (human)
dopamine catabolic processDopamine beta-hydroxylase Bos taurus (cattle)
norepinephrine biosynthetic processDopamine beta-hydroxylase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
catalytic activityDopamine beta-hydroxylaseHomo sapiens (human)
dopamine beta-monooxygenase activityDopamine beta-hydroxylaseHomo sapiens (human)
copper ion bindingDopamine beta-hydroxylaseHomo sapiens (human)
protein bindingDopamine beta-hydroxylaseHomo sapiens (human)
L-ascorbic acid bindingDopamine beta-hydroxylaseHomo sapiens (human)
dopamine beta-monooxygenase activityDopamine beta-hydroxylase Bos taurus (cattle)
copper ion bindingDopamine beta-hydroxylase Bos taurus (cattle)
L-ascorbic acid bindingDopamine beta-hydroxylase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylaseHomo sapiens (human)
cytoplasmDopamine beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulumDopamine beta-hydroxylaseHomo sapiens (human)
membraneDopamine beta-hydroxylaseHomo sapiens (human)
transport vesicle membraneDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
centriolar satelliteDopamine beta-hydroxylaseHomo sapiens (human)
chromaffin granule lumenDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule lumenDopamine beta-hydroxylaseHomo sapiens (human)
chromaffin granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
intracellular membrane-bounded organelleDopamine beta-hydroxylaseHomo sapiens (human)
synapseDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylase Bos taurus (cattle)
transport vesicle membraneDopamine beta-hydroxylase Bos taurus (cattle)
chromaffin granule lumenDopamine beta-hydroxylase Bos taurus (cattle)
secretory granule lumenDopamine beta-hydroxylase Bos taurus (cattle)
chromaffin granule membraneDopamine beta-hydroxylase Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID173884Antihypertensive activity was determined by decrease in blood pressure response in spontaneously hypertensive rat was determined after intraperitoneal administration at a dose of 50 mg/kg1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones.
AID61961Inhibitory Concentration against bovine Dopamine beta hydroxylase (DBH); Range is between (1.3-4.6)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID62126Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH 4.5.1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID62122Compound was evaluated for the inhibition of Dopamine beta hydroxylase at pH 6.61986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione.
AID23486Partition coefficient (logP)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID184114Percent increase in DA/NE ratio was determined from assay of DA and NE in the mesenteric artery of spontaneously hypertensive rat after two doses for 50 mg/kg peroral administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones.
AID61955Inhibition of Dopamine beta hydroxylase.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione.
AID193786Change in DA/NE (Dopamine/Norepinephrine) ratio after oral dosing (50 mg/kg)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID62131Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH 61987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID193201Mean arterial blood pressure at 4 hr post drug at ip dose of 50 mg/kg for the indicated number of SHR (spontaneous hypertensive rats) relative to blood pressure before dosing1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID229988In vivo evaluation ot the compound in spontaneously hypertensive rats for the catecholamine levels by taking the ratio of dopamine to norepinephrine1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.
AID62150Inhibition of Dopamine beta hydroxylase in spontaneously hypertensive rats; Value ranges from 1.3-4.61987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones.
AID62278Inhibition of dopamine beta-hydroxylase (DbetaH) in hypertensive rats when administered orally (or) intraperitoneally1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
1-(substituted-benzyl)imidazole-2(3H)-thione inhibitors of dopamine beta-hydroxylase.
AID62136Inhibitor dissociation constant vs. tyramine substrate against Dopamine beta hydroxylase at pH 6.61987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID62281Inhibition of dopamine beta-hydroxylase (DbetaH) enzyme1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID62121Compound was evaluated for the inhibition of Dopamine beta hydroxylase at pH 4.51986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione.
AID61993Binding affinity towards Dopamine beta hydroxylase using tyramine substrate at pH 4.5 in the absence of fumarate1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.
AID186842In vivo evaluation ot the compound in spontaneously hypertensive rats for the mean arterial blood pressure1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase.
AID193204Mean arterial blood pressure at 4 hr post drug at po dose of 50 mg/kg for the indicated number of SHR (spontaneous hypertensive rats) relative to blood pressure before dosing1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site.
AID62155Inhibition of dopamine beta hydroxylase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Receptor surface models. 2. Application to quantitative structure-activity relationships studies.
AID62275Inhibitory activity was determined against bovine dopamine beta-hydroxylase (DBH)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine beta-hydroxylase. 4. Structure-activity relationships at the copper binding site.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (23.81)18.7374
1990's4 (19.05)18.2507
2000's2 (9.52)29.6817
2010's5 (23.81)24.3611
2020's5 (23.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]